TrialAssure, a global software company focused on developing clinical trial transparency tools-announced that it will offer academic institutions free access to TrialAssure REGISTRY-the clinical trial disclosure reporting application. This offer is limited to the registry configurations for ClinicalTrials.gov, the US Food & Drug Administration (FDA) clinical trial registry, and it includes one upgrade per year, keeping with technological advancements and any US regulatory updates or changes to registry requirements.
Academic institutions can sign up for a TrialAssure subscription specific to this program-at no cost- allowing users free access for up to two years. TrialAssure, in providing access to the REGISTRY application, will ask participating academic institutions to make a commitment to transparency in research, including measured improvements to their registry compliance over a two-year period.
“We want to make sure that every clinical trial is reported in a timely manner, and our goal is to provide the tools to help where the need is most evident-in the academic setting,” says Mohamad Zahreddine, Chief Information Officer, TrialAssure, and member of the Forbes Technology Council. “With our intuitive registration and results posting capabilities, academic institutions will have the tools they need to achieve full compliance with applicable government requirements.”
Government regulations in the US and other global health authorities require the registration and subsequent posting of summary results for clinical trials. However, in review of compliance in the US, only 34% of clinical trials sponsored by academic institutions and similar groups are likely to be reported on-time, according to AllTrials.
With this free, limited-time academic subscription program, institutions will have up to three professional and 20 reviewer level users within the TrialAssure REGISTRY application. As always with the TrialAssure suite, subscribers will own and manage their data directly and have access to full training documentation. There is no requirement for TrialAssure colleagues to intervene or conduct any activities on behalf of the subscriber, unless the subscriber requests this assistance and facilitation.
“Some may ask why we initiated this program and are giving this subscription away for free,” says Kelly Vaillant, Director, Global Transparency Strategy & Compliance, TrialAssure. “The answer is simple: TrialAssure believes that data transparency advances science and the development of new medicines. As an industry, we have a responsibility and obligation to make information about clinical trials available in a way that protects the patient’s privacy but also allows for the benefits to science. If we can help organizations enhance transparency across their clinical research activities, which is needed, it’s a strong step in the right direction.”
Academic institutions have six months (until October 7, 2020) to express interest in this program. Those interested in gaining a free subscription can fill out this form: https://www.trialassure.com/contact-us/
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.